If You Invested in IM Cannabis Corp. (IMCC)

IM Cannabis Corp. (Nasdaq: IMCC) is an international cannabis company focused on serving medical patients in Israel and Germany. Across these two medical cannabis markets, the company provides premium cannabis products through an integrated operating model that combines import, distribution, retail pharmacies, and digital platforms. IM Cannabis emphasizes a data-driven approach and a globally sourced product supply chain to support its commercial activities.

Business focus and operating footprint

According to the company’s public disclosures, IM Cannabis concentrates its resources on achieving sustainable and profitable growth in its highest value markets, Israel and Germany. The company describes itself as a medical cannabis company with operations in both countries, where it supplies cannabis products for medical use.

In Israel, the IM Cannabis ecosystem operates through subsidiaries that import and distribute cannabis to medical patients. These operations are described as leveraging years of proprietary data and patient insights. The company also operates medical cannabis retail pharmacies and online platforms in Israel, as well as distribution centers and logistical hubs that support safe delivery and quality control of its products throughout the value chain.

In Germany, IM Cannabis operates through Adjupharm GmbH. Through this subsidiary, the company distributes cannabis to pharmacies that serve medical cannabis patients. Germany is highlighted by the company as one of its key medical cannabis markets.

Transnational ecosystem and data-driven approach

IM Cannabis repeatedly characterizes its operations as a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. This ecosystem spans import and distribution activities, retail pharmacy operations, and online channels. The company states that it uses proprietary data and patient insights in Israel to inform how it serves medical cannabis patients and manages product delivery and quality.

The company also emphasizes its focus on compliance with strict regulatory environments in the jurisdictions where it operates. It describes an unwavering commitment to responsible growth and regulatory compliance as part of its effort to strengthen its commercial and brand position in the medical cannabis sector.

Core activities in Israel

In Israel, IM Cannabis’ operations include:

• Importing and distributing cannabis to medical patients through its subsidiaries.
• Using proprietary data and patient insights accumulated over years of activity.
• Operating medical cannabis retail pharmacies that dispense products to patients.
• Running online platforms that support ordering and access to IMC products.
• Managing distribution centers and logistical hubs that enable safe delivery and quality control across the entire value chain.

These activities are described by the company as supporting the safe delivery of products and maintaining quality control from import through to the patient.

Core activities in Germany

In Germany, IM Cannabis operates through its subsidiary Adjupharm GmbH. The company states that Adjupharm distributes cannabis to pharmacies for medical cannabis patients. This positions IM Cannabis within the regulated German medical cannabis supply chain, with pharmacies as the direct point of contact for patients.

Strategic priorities and additional business activities

IM Cannabis has disclosed that it is conducting an ongoing strategic review and has decided to explore the introduction of additional business activities. The stated goal of this effort is to enhance long-term growth opportunities and create further shareholder value. As part of this strategic direction, the company announced the signing of a non-binding indicative term sheet for a proposed securities exchange agreement to acquire a 60% equity interest in a quantum computing bio data company, subject to due diligence, definitive agreements, regulatory approvals, and customary closing conditions.

The company has also announced that it is actively evaluating strategic opportunities to expand its operations into the United States cannabis market. To support this evaluation, IM Cannabis engaged SSC Advisors as exclusive financial advisors for potential U.S. opportunities and possible divestitures of its businesses in Germany and Israel. These activities are framed as part of the company’s broader strategic review and response to regulatory developments related to medical marijuana and cannabidiol research in the United States.

Regulatory and listing context

IM Cannabis is a foreign private issuer that files reports with the U.S. Securities and Exchange Commission, including Form 20-F and multiple Form 6-K current reports. The company’s common shares trade on the Nasdaq Capital Market under the symbol IMCC. In a public announcement, IM Cannabis reported that it regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least a specified threshold, and that its common stock continues to be listed and traded on the Nasdaq Capital Market.

Corporate governance and board developments

The company has reported several changes in its leadership and board composition through press releases and Form 6-K filings. These include the appointment of a new Chief Financial Officer, the planned departure of the previous Chief Financial Officer, and changes to the board of directors and its committees. The board also appointed a new Chairman while the existing Chief Executive Officer continues to serve as CEO and as a director.

IM Cannabis has indicated that its directors and executives enter into standard indemnification agreements and that certain board appointments are not associated with related party transactions requiring disclosure under applicable rules. These disclosures provide insight into the company’s governance practices and oversight structure.

Financial reporting and risk disclosures

IM Cannabis provides interim condensed consolidated financial statements and management’s discussion and analysis (MD&A) for its reporting periods via Form 6-K filings. In connection with its financial reporting, the company has discussed non-IFRS measures such as Gross Margin and Adjusted EBITDA, explaining that these measures are intended as complementary information to IFRS metrics.

The company’s disclosures include a detailed cautionary note regarding forward-looking statements and risk factors. Among the risks identified are regulatory changes in the jurisdictions where it operates, the ability to maintain listing requirements on the Nasdaq Capital Market, reliance on third-party supply agreements for medical cannabis, exposure to product liability and safety-related risks, competition, supply chain constraints, dependence on key personnel, and geopolitical risks, including conflicts in the Middle East and Eastern Europe. IM Cannabis also notes the risks associated with focusing on the Israel and Germany markets and the challenges of achieving sustainable profitability and executing strategic plans.

Strategic review and capital markets activity

In addition to its operating activities, IM Cannabis has undertaken capital markets transactions and related steps. The company amended certain common share purchase warrants originally issued in a prior private placement by reducing the exercise price and extending the expiration date. It also filed a resale registration statement on Form F-3 with the SEC to register common shares and shares underlying various warrants and pre-funded warrants, allowing selling shareholders to potentially resell these securities if the registration statement becomes effective.

The company has also disclosed related party participation in warrant amendments and has filed early warning reports in Canada in connection with securities holdings of insiders and their joint actors. These filings outline ownership levels, warrant and option positions, and convertible debentures held by certain insiders.

Position within the medicinal and botanical manufacturing sector

Within the broader medicinal and botanical manufacturing industry, IM Cannabis positions itself as a company focused on medical cannabis products and related distribution infrastructure. Its activities span importation, distribution, retail pharmacy operations, and online platforms in Israel, alongside distribution to pharmacies in Germany through Adjupharm GmbH. The company’s emphasis on data, patient insights, and regulatory compliance reflects the requirements of operating in tightly regulated medical cannabis markets.